CryoLife, Inc. (NYSE:CRY) – Analysts at First Analysis issued their Q3 2018 earnings estimates for shares of CryoLife in a report issued on Tuesday. First Analysis analyst expects that the medical equipment provider will post earnings per share of $0.02 for the quarter.

CRY has been the subject of a number of other research reports. BidaskClub cut shares of CryoLife from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. TheStreet cut shares of CryoLife from a “b” rating to a “c+” rating in a report on Monday, October 30th. Zacks Investment Research cut shares of CryoLife from a “buy” rating to a “sell” rating in a report on Wednesday, August 2nd. Northland Securities restated a “buy” rating and set a $23.50 price objective on shares of CryoLife in a report on Monday. Finally, Lake Street Capital boosted their price objective on shares of CryoLife to $26.00 and gave the company a “buy” rating in a report on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. CryoLife has an average rating of “Hold” and a consensus price target of $23.63.

TRADEMARK VIOLATION WARNING: “CryoLife, Inc. (CRY) to Post Q3 2018 Earnings of $0.02 Per Share, First Analysis Forecasts” was originally reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/17/cryolife-inc-cry-to-post-q3-2018-earnings-of-0-02-per-share-first-analysis-forecasts.html.

Shares of CryoLife (NYSE:CRY) traded down $0.15 during midday trading on Friday, reaching $19.20. 70,290 shares of the company were exchanged, compared to its average volume of 163,794. The firm has a market capitalization of $647.40, a PE ratio of 47.19 and a beta of 0.82. The company has a debt-to-equity ratio of 0.29, a quick ratio of 4.90 and a current ratio of 5.96. CryoLife has a 52-week low of $14.02 and a 52-week high of $24.00.

CryoLife (NYSE:CRY) last issued its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.08. The firm had revenue of $44.00 million during the quarter, compared to analysts’ expectations of $44.60 million. CryoLife had a net margin of 5.28% and a return on equity of 6.43%. The business’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.13 earnings per share.

Several hedge funds have recently made changes to their positions in the company. Dimensional Fund Advisors LP lifted its position in shares of CryoLife by 1.8% in the third quarter. Dimensional Fund Advisors LP now owns 1,994,820 shares of the medical equipment provider’s stock worth $45,282,000 after purchasing an additional 34,599 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of CryoLife by 6.6% in the second quarter. Vanguard Group Inc. now owns 1,658,646 shares of the medical equipment provider’s stock worth $33,090,000 after purchasing an additional 102,540 shares in the last quarter. Macquarie Group Ltd. lifted its position in shares of CryoLife by 16.0% in the third quarter. Macquarie Group Ltd. now owns 1,609,284 shares of the medical equipment provider’s stock worth $36,531,000 after purchasing an additional 221,574 shares in the last quarter. Northern Trust Corp lifted its position in shares of CryoLife by 7.4% in the second quarter. Northern Trust Corp now owns 1,171,769 shares of the medical equipment provider’s stock worth $23,377,000 after purchasing an additional 81,090 shares in the last quarter. Finally, State Street Corp lifted its position in shares of CryoLife by 5.2% in the second quarter. State Street Corp now owns 758,840 shares of the medical equipment provider’s stock worth $15,143,000 after purchasing an additional 37,279 shares in the last quarter. 70.34% of the stock is currently owned by institutional investors and hedge funds.

In other CryoLife news, VP David C. Gale sold 20,000 shares of CryoLife stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $19.63, for a total value of $392,600.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO James P. Mackin sold 43,050 shares of CryoLife stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $22.09, for a total transaction of $950,974.50. Following the completion of the transaction, the chief executive officer now directly owns 398,399 shares in the company, valued at approximately $8,800,633.91. The disclosure for this sale can be found here. In the last ninety days, insiders sold 229,240 shares of company stock worth $4,888,065. Insiders own 6.00% of the company’s stock.

About CryoLife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Earnings History and Estimates for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.